Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Breast Cancer
Interventions
DRUG

Vorinostat

Vorinostat 200 or 300 mg PO BID on days 1-3 of each weekly paclitaxel dose

DRUG

Paclitaxel

Paclitaxel 80 mg/m2 weekly for 12 weeks

DRUG

Trastuzumab

Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose

DRUG

Doxorubicin

Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks

DRUG

Cyclophosphamide

Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks

PROCEDURE

Surgery

Surgical excision of tumor from breast

Trial Locations (1)

10461

Montefiore Medical Center, The Bronx

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Albert Einstein College of Medicine

OTHER

NCT00574587 - Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy | Biotech Hunter | Biotech Hunter